Limits...
Relationship between serotonin transporter gene polymorphism and constipation in cancer patients.

Li W, Huang L, Cai W, Cao S, Yuan Y, Lu S, Zhao Y, Lu P - Contemp Oncol (Pozn) (2015)

Bottom Line: A total of 120 patients diagnosed with malignant solid tumors were subjected to genotyping.We extracted genomic DNA, and used polymerase chain reaction (PCR) to analyze the serotonin transporter (5-HT) link polymorphic region (5-HTTLPR) polymorphism of the serotonin transporter gene.There was a significant difference between the two groups (p < 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, the 1 Affiliated Hospital of Xinxiang Medical University, Xinxiang Henan Prov., PR China.

ABSTRACT

Introduction: To assess the potential association between serotonin transporter gene insertion/deletion polymorphism and the cancer-related constipation phenotype.

Material and methods: A total of 120 patients diagnosed with malignant solid tumors were subjected to genotyping. For the two groups - patients with constipation and constipation-free patients with non-gastrointestinal cancer, 60 cases in each group - we collected the peripheral venous blood. We extracted genomic DNA, and used polymerase chain reaction (PCR) to analyze the serotonin transporter (5-HT) link polymorphic region (5-HTTLPR) polymorphism of the serotonin transporter gene.

Results: The frequency of S/S genotype in cancer patients with constipation was 66.67% (40/60), and the frequency of the S allele was 79.17% (95/120); the frequency of S/S genotype in cancer patients without constipation was 48.33% (29/60), and the frequency of the S allele was 65.83% (79/120). There was a significant difference between the two groups (p < 0.05).

Conclusions: The presence of 5-HTTLPRS/S genotype and the S allele in patients with cancers probably carry an increased risk of constipation. However, its role as a cause of cancer-related constipation needs to be further investigated.

No MeSH data available.


Related in: MedlinePlus

Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4507894&req=5

Figure 0001: Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis

Mentions: Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis are shown in Fig. 1. The product sizes of the insertion (L) and deletion (S) alleles were 419 bp and 375 bp, respectively.


Relationship between serotonin transporter gene polymorphism and constipation in cancer patients.

Li W, Huang L, Cai W, Cao S, Yuan Y, Lu S, Zhao Y, Lu P - Contemp Oncol (Pozn) (2015)

Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4507894&req=5

Figure 0001: Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis
Mentions: Amplified products of the 5-HTTLPR gene separated by agarose electrophoresis are shown in Fig. 1. The product sizes of the insertion (L) and deletion (S) alleles were 419 bp and 375 bp, respectively.

Bottom Line: A total of 120 patients diagnosed with malignant solid tumors were subjected to genotyping.We extracted genomic DNA, and used polymerase chain reaction (PCR) to analyze the serotonin transporter (5-HT) link polymorphic region (5-HTTLPR) polymorphism of the serotonin transporter gene.There was a significant difference between the two groups (p < 0.05).

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, the 1 Affiliated Hospital of Xinxiang Medical University, Xinxiang Henan Prov., PR China.

ABSTRACT

Introduction: To assess the potential association between serotonin transporter gene insertion/deletion polymorphism and the cancer-related constipation phenotype.

Material and methods: A total of 120 patients diagnosed with malignant solid tumors were subjected to genotyping. For the two groups - patients with constipation and constipation-free patients with non-gastrointestinal cancer, 60 cases in each group - we collected the peripheral venous blood. We extracted genomic DNA, and used polymerase chain reaction (PCR) to analyze the serotonin transporter (5-HT) link polymorphic region (5-HTTLPR) polymorphism of the serotonin transporter gene.

Results: The frequency of S/S genotype in cancer patients with constipation was 66.67% (40/60), and the frequency of the S allele was 79.17% (95/120); the frequency of S/S genotype in cancer patients without constipation was 48.33% (29/60), and the frequency of the S allele was 65.83% (79/120). There was a significant difference between the two groups (p < 0.05).

Conclusions: The presence of 5-HTTLPRS/S genotype and the S allele in patients with cancers probably carry an increased risk of constipation. However, its role as a cause of cancer-related constipation needs to be further investigated.

No MeSH data available.


Related in: MedlinePlus